Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 8Breast Neoplasms 8Neoplasm Metastasis 7Lung Neoplasms 6Rectal Neoplasms 5Sarcoma 4Prostatic Neoplasms 4Melanoma 4Colonic Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thymoma 2Neoplasms 2Mouth Neoplasms 2Head and Neck Neoplasms 2Carcinoma 2Adenomatous Polyposis Coli 2Uterine Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paranasal Sinus Neoplasms 1Papilloma 1Pain 1

Interventions

Celecoxib 2rofecoxib 1obeticholic acid 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Endoscopy, Gastrointestinal 1Duration of Therapy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Adenomatous Polyposis Coli × Celecoxib × Clear all
NCT00151476 2024-09-04

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Pfizer

Terminated
68 enrolled 22 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00585312 2021-02-21

CHIP

Pfizer

Phase 3 Terminated
106 enrolled 10 charts
Gastrointestinal

Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡